NO20055747L - Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin - Google Patents
Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbuminInfo
- Publication number
- NO20055747L NO20055747L NO20055747A NO20055747A NO20055747L NO 20055747 L NO20055747 L NO 20055747L NO 20055747 A NO20055747 A NO 20055747A NO 20055747 A NO20055747 A NO 20055747A NO 20055747 L NO20055747 L NO 20055747L
- Authority
- NO
- Norway
- Prior art keywords
- human erythropoietin
- serum albumin
- aqueous solutions
- stable aqueous
- contain serum
- Prior art date
Links
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 title abstract 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 title abstract 3
- 102000044890 human EPO Human genes 0.000 title abstract 3
- 102000007562 Serum Albumin Human genes 0.000 title abstract 2
- 108010071390 Serum Albumin Proteins 0.000 title abstract 2
- 239000007864 aqueous solution Substances 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000003139 buffering effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20030037060 | 2003-06-10 | ||
| PCT/KR2004/001358 WO2004108152A1 (en) | 2003-06-10 | 2004-06-07 | Stable, aqueous solution of human erythropoietin, not containing serum albumin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20055747D0 NO20055747D0 (no) | 2005-12-05 |
| NO20055747L true NO20055747L (no) | 2006-03-07 |
Family
ID=36337525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055747A NO20055747L (no) | 2003-06-10 | 2005-12-05 | Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8119595B2 (pl) |
| EP (1) | EP1641486B1 (pl) |
| JP (1) | JP4871720B2 (pl) |
| KR (1) | KR100610003B1 (pl) |
| CN (1) | CN1802171B (pl) |
| AT (1) | ATE553747T1 (pl) |
| AU (1) | AU2004244920B2 (pl) |
| BR (1) | BRPI0411114B8 (pl) |
| CA (1) | CA2528988C (pl) |
| EA (1) | EA009676B1 (pl) |
| ES (1) | ES2385888T3 (pl) |
| MX (1) | MXPA05013398A (pl) |
| NO (1) | NO20055747L (pl) |
| NZ (1) | NZ543859A (pl) |
| PL (1) | PL379272A1 (pl) |
| UA (1) | UA82241C2 (pl) |
| WO (1) | WO2004108152A1 (pl) |
| ZA (1) | ZA200509222B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
| JP5553506B2 (ja) * | 2006-03-22 | 2014-07-16 | 中外製薬株式会社 | エリスロポエチン溶液製剤 |
| DE102007050165B4 (de) * | 2007-10-19 | 2010-06-17 | Stiftung Tierärztliche Hochschule Hannover | Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung |
| US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| PE20110543A1 (es) * | 2008-08-15 | 2011-08-04 | Ironwood Pharmaceuticals Inc | Formulacion solida oral que comprende linaclotida, cation de calcio y leucina |
| CA2770077A1 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| BR112012017982A2 (pt) * | 2010-01-19 | 2016-05-03 | Hanmi Science Co Ltd | formulações líquidas para conjugado de eritropoietina de longa ação |
| UA108636C2 (xx) | 2010-02-17 | 2015-05-25 | Пептид | |
| EP2603232B1 (en) | 2010-08-11 | 2019-09-25 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| MX347354B (es) | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | Tratamientos para trastornos gastrointestinales. |
| EP2968468B1 (en) * | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| CN107708723B (zh) * | 2015-04-21 | 2021-04-13 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子组合物和注射粉剂 |
| CN118338910A (zh) * | 2021-12-03 | 2024-07-12 | 杰科（天津）生物医药有限公司 | 一种制剂及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| ATE383169T1 (de) * | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
| TW570805B (en) * | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| WO2000015241A1 (fr) * | 1998-09-11 | 2000-03-23 | Chugai Seiyaku Kabushiki Kaisha | Preparation d'une solution proteinique et son procede de stabilisation |
| CA2369444C (en) * | 1999-04-09 | 2009-08-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
| AU6875900A (en) * | 1999-09-08 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Protein solution preparation and method of stabilizing the same |
| US7163671B2 (en) * | 2000-02-29 | 2007-01-16 | Chugai Seiyaku Kabushiki Kaisha | Long-term stabilized formulations |
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| SI21258A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol |
-
2004
- 2004-06-07 EP EP04773889A patent/EP1641486B1/en not_active Expired - Lifetime
- 2004-06-07 EA EA200501789A patent/EA009676B1/ru not_active IP Right Cessation
- 2004-06-07 AU AU2004244920A patent/AU2004244920B2/en not_active Expired
- 2004-06-07 WO PCT/KR2004/001358 patent/WO2004108152A1/en not_active Ceased
- 2004-06-07 NZ NZ543859A patent/NZ543859A/en not_active IP Right Cessation
- 2004-06-07 AT AT04773889T patent/ATE553747T1/de active
- 2004-06-07 PL PL379272A patent/PL379272A1/pl unknown
- 2004-06-07 CN CN2004800159563A patent/CN1802171B/zh not_active Expired - Lifetime
- 2004-06-07 JP JP2006516913A patent/JP4871720B2/ja not_active Expired - Fee Related
- 2004-06-07 US US10/560,374 patent/US8119595B2/en active Active
- 2004-06-07 KR KR1020040041294A patent/KR100610003B1/ko not_active Ceased
- 2004-06-07 ES ES04773889T patent/ES2385888T3/es not_active Expired - Lifetime
- 2004-06-07 CA CA2528988A patent/CA2528988C/en not_active Expired - Fee Related
- 2004-06-07 BR BRPI0411114A patent/BRPI0411114B8/pt not_active IP Right Cessation
- 2004-06-07 MX MXPA05013398A patent/MXPA05013398A/es active IP Right Grant
- 2004-07-06 UA UAA200600164A patent/UA82241C2/uk unknown
-
2005
- 2005-11-15 ZA ZA200509222A patent/ZA200509222B/xx unknown
- 2005-12-05 NO NO20055747A patent/NO20055747L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070293419A1 (en) | 2007-12-20 |
| US8119595B2 (en) | 2012-02-21 |
| CA2528988C (en) | 2012-05-01 |
| BRPI0411114A (pt) | 2006-07-18 |
| ATE553747T1 (de) | 2012-05-15 |
| JP4871720B2 (ja) | 2012-02-08 |
| AU2004244920A1 (en) | 2004-12-16 |
| CN1802171B (zh) | 2010-10-13 |
| JP2007528842A (ja) | 2007-10-18 |
| KR20040110994A (ko) | 2004-12-31 |
| HK1093012A1 (en) | 2007-02-23 |
| EA009676B1 (ru) | 2008-02-28 |
| WO2004108152A1 (en) | 2004-12-16 |
| EP1641486A1 (en) | 2006-04-05 |
| PL379272A1 (pl) | 2006-08-21 |
| MXPA05013398A (es) | 2006-03-09 |
| KR100610003B1 (ko) | 2006-08-08 |
| BRPI0411114B1 (pt) | 2020-09-15 |
| BRPI0411114B8 (pt) | 2021-05-25 |
| ES2385888T3 (es) | 2012-08-02 |
| UA82241C2 (uk) | 2008-03-25 |
| AU2004244920B2 (en) | 2009-07-23 |
| NO20055747D0 (no) | 2005-12-05 |
| EA200501789A1 (ru) | 2006-06-30 |
| EP1641486A4 (en) | 2008-10-08 |
| ZA200509222B (en) | 2006-09-27 |
| NZ543859A (en) | 2008-01-31 |
| CN1802171A (zh) | 2006-07-12 |
| EP1641486B1 (en) | 2012-04-18 |
| CA2528988A1 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055747D0 (no) | Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin | |
| DE60334678D1 (de) | Antikörper enthaltende pharmazeutische lösungen | |
| WO2009013435A3 (fr) | Solution ophtalmique à base de prostaglandines sans conservateur | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| WO2007069214A3 (en) | Wet wipes with natural antimicrobial agents | |
| WO2013016648A3 (en) | Stabilized formulations containing anti-pcsk9 antibodies | |
| DK1605932T3 (da) | Intranasal formulering af rotigotin | |
| CR10032A (es) | Preparación sólida | |
| AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
| WO2010068440A3 (en) | Low ph oral care compositions with fused silica and a fluoride source | |
| MX2007012443A (es) | Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales. | |
| MA33023B1 (fr) | Formulation d'anticorps | |
| JO3417B1 (ar) | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r | |
| DK1372608T3 (da) | Medicinske aerosolformuleringer | |
| WO2004091656A3 (fr) | Formulation stabilisante pour compositions d'immunoglobulines G sous forme liquide et sous forme lyophilisEe | |
| ATE554792T1 (de) | Stabiles wachstumshormon-flüssigformulierung | |
| WO2006110482A3 (en) | Borate-polyol mixtures as a buffering system | |
| WO2003057153A3 (en) | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol | |
| FR2881349B1 (fr) | Nouvelle utilisation des galactomannanes en tant qu'agent actif en cosmetique. | |
| NO20065791L (no) | Asyklovir-formuleringer | |
| WO2005060361A3 (en) | Pharmaceutical formulations for itraconazole | |
| EA200701776A1 (ru) | Композиция для ухода за контактными линзами | |
| HN2004000123A (es) | Composición agroquimica en suspensión acuosa | |
| FR2886846B1 (fr) | Nouvelles utilisations de derives du glycerol, notamment dans le domaine cosmetique | |
| BRPI0504082A (pt) | emulsões refrescantes medicinais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |